Literature DB >> 10227768

Immusorba TR and Immusorba PH: basics of design and features of functions.

M Yoshida, Y Tamura, Y Yamada, N Yamawaki, Y Yamashita.   

Abstract

Immusorba was reported by Yamazaki et al. to be the world's first practical immunoadsorbent in 1982. Since then, this immunoadsorbent has accumulated an abundance of clinical achievements. Immusorba has such unique functions that it is used in treating various diseases and holds possibilities for application to more diseases. Immusorba was designed as an artificial receptor for rheumatoid factor (RF) based on structural analysis of heat-denaturated globulin. Subsequently, new substances that it can adsorb have been found as seen in reports on the adsorption performance of Immusorba to anti-acetylcholine receptor antibodies (anti-AChR Abs) and antiganglioside antibodies. Along with this, Immusorba has been used in treating a wide range of diseases. The greatest characteristic of Immusorba is that its adsorption capability is selective rather than specific, making it effective against a great number of diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10227768     DOI: 10.1111/j.1744-9987.1998.tb00102.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  3 in total

Review 1.  B cells in MS and NMO: pathogenesis and therapy.

Authors:  Markus Krumbholz; Edgar Meinl
Journal:  Semin Immunopathol       Date:  2014-05-16       Impact factor: 9.623

2.  Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.

Authors:  Michael J Koziolek; Desiree Tampe; Matthias Bähr; Hassan Dihazi; Klaus Jung; Dirk Fitzner; Reinhard Klingel; Gerhard A Müller; Bernd Kitze
Journal:  J Neuroinflammation       Date:  2012-04-26       Impact factor: 8.322

3.  Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption.

Authors:  Roberto De Masi; Salvatore Accoto; Stefania Orlando; Vincenzo De Blasi; Sergio Pasca; Rocco Scarpello; Leo Spagnolo; Adele Idolo; Antonella De Donno
Journal:  BMC Neurol       Date:  2015-07-31       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.